GlassScriptPhysician profile
Paul S Panzarella
NPI 1275813057
$20,637.69
in general payments reported to CMS, 2019-2025
48 companies · $10K in 2025
The $10K reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,672 · 2020: $701 · 2021: $1,322 · 2022: $1,751 · 2023: $2,248 · 2024: $2,589 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,662 · Consulting Fee: $7,500 · Education: $28.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,662.27 |
| Consulting Fee | $7,500.00 |
| Education | $28.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $7,866.32 | 2023-2025 | |
| Abbvie INC. | $4,140.84 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,694.38 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Phathom Pharmaceuticals, INC. | $740.33 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $698.51 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $566.70 | 2019-2025 | |
| Celgene Corporation | $489.65 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $479.30 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $442.20 | 2021-2023 | |
| Janssen Biotech, INC. | $438.21 | 2021-2025 | Stelara, Tremfya, Simponi |
| Madrigal Pharmaceuticals | $319.22 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $291.48 | 2024-2025 | Zenpep |
| Genzyme Corporation | $278.94 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $234.39 | 2022-2025 | Dupixent |
| Redhill Biopharma INC. | $169.26 | 2020-2022 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $161.10 | 2021-2025 | Interstim |
| Ipsen Biopharmaceuticals, INC | $116.25 | 2024-2025 | Iqirvo |
| Qol Medical, LLC | $114.86 | 2020-2023 | Sucraid |
| Ardelyx, INC. | $110.02 | 2023-2024 | Ibsrela |
| Vivus LLC | $107.12 | 2019-2022 | |
| Celltrion USA INC. | $102.27 | 2024-2025 | Vegzelma, Zymfentra |
| Amgen INC. | $98.42 | 2023-2025 | Amjevita, Avsola, Uplizna |
| Allergan, INC. | $98.29 | 2019-2020 | |
| Evoke Pharma, INC. | $91.92 | 2022-2025 | Gimoti |
| Lilly USA, LLC | $84.62 | 2025 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.77 | 2023-2024 | Cyltezo |
| Intercept Pharmaceuticals, INC. | $62.43 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $46.07 | 2023 | Idacio |
| Romark Laboratories, Lc | $43.11 | 2019 | |
| Alnylam Pharmaceuticals INC. | $42.40 | 2021-2022 | |
| Ucb, INC. | $41.85 | 2019 | |
| Boston Scientific Corporation | $41.27 | 2023 | Compliance Endokit |
| Braintree Laboratories, INC. | $37.00 | 2024 | Suflave, Sutab |
| Shionogi INC | $36.17 | 2019 | |
| Daiichi Sankyo INC. | $34.60 | 2019-2022 | |
| Ethicon US, LLC | $30.55 | 2019 | |
| Ironwood Pharmaceuticals, INC | $26.59 | 2019-2020 | |
| Novo Nordisk INC | $24.06 | 2025 | Wegovy |
| Enterra Medical, INC. | $23.56 | 2024 | |
| Concordia Pharmaceuticals INC. | $23.09 | 2019 | |
| Merck Sharp & Dohme LLC | $19.47 | 2023 | Dificid, Recarbrio |
| Alfasigma USA, INC. | $17.16 | 2020 | |
| Shire North American Group INC | $14.53 | 2019 | |
| Covidien LP | $13.83 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.61 | 2024 | Rebyota |
| Medtronic USA, INC. | $12.41 | 2020 | |
| Endo Pharmaceuticals INC. | $12.08 | 2020 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Panzarella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.